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Abstract 
 
Phenylketonuria, an autosomal recessive Mendelian disorder, is one of the most 
common inborn errors of metabolism.  Although currently treated by diet, many 
suboptimal outcomes occur for patients.  Neuropathological outcomes include 
cognitive loss, white matter abnormalities, and hypo- or demyelination, resulting 
from high concentrations and/or fluctuating levels of phenylalanine.  High 
phenylalanine can also result in competitive exclusion of other large neutral 
amino acids from the brain, including tyrosine and tryptophan (essential 
precursors of dopamine and serotonin).  This competition occurs at the blood 
brain barrier, where the L-type amino acid transporter, LAT1, selectively 
facilitates entry of large neutral amino acids.  The hypothesis of these studies is 
that certain non-physiological amino acids (NPAA; DL-norleucine (NL), 2-
aminonorbornane (NB; 2-aminobicyclo-(2,1,1)-heptane-2-carboxylic acid), α-
aminoisobutyrate (AIB), and α-methyl-aminoisobutyrate (MAIB)) would 
competitively inhibit LAT1 transport of phenylalanine (Phe) at the blood-brain 
barrier interface.  To test this hypothesis, Pah-/- mice (n=5, mixed gender; Pah+/- 
(n=5) as controls) were fed either 5% NL, 0.5% NB, 5% AIB or 3% MAIB (w/w 
18% protein mouse chow) for 3 weeks.  Outcome measurements included food 
intake, body weight, brain LNAAs, and brain monoamines measured via LC-
MS/MS or HPLC.  Brain Phe values at sacrifice were significantly reduced for NL, 
NB, and MAIB, verifying the hypothesis that these NPAAs could inhibit Phe 
trafficking into the brain.  However, concomitant reductions in tyrosine and 
methionine occurred at the concentrations employed.   Blood Phe levels were not 
altered indicating no effect of NPAA competitors in the gut.  Brain NL and NB 
levels, measured with HPLC, verified both uptake and transport of NPAAs.  
Although believed predominantly unmetabolized, NL feeding significantly 
increased blood urea nitrogen.  Pah-/- disturbances of monoamine metabolism 
were exacerbated by NPAA intervention, primarily with NB (the prototypical LAT 
inhibitor).  To achieve the overarching goal of using NPAAs to stabilize Phe 
transport levels into the brain, a specific Phe-reducing combination and 
concentration of NPAAs must be found.   
 
Our studies represent the first in vivo use of NL, NB and MAIB in Pah-/- mice, and 
provide proof-of-principle for further characterization of these LAT inhibitors.  Our 
data is the first to document an effect of MAIB, a specific system A transport 
inhibitor, on large neutral amino acid transport.   
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1. Introduction 
 
1.1. Phenylketonuria 
 
Phenylketonuria (PKU) is an autosomal recessive disorder, which affects more 
individuals than any other inherited disorder of amino acid metabolism (U.S. 
frequency 1:15,000).  The disease was first discovered by Asbjorn Følling in 
1934, who recorded high levels of phenylpyruvic acid (keto-phenylpyruvate) in 
the urine of two mentally impaired siblings (Følling 1994).  In PKU, the deficiency 
of phenylalanine hydroxylase, PAH, leads to pathological levels of phenylalanine 
(Phe) in the brain and blood, normal to low levels of tyrosine (Tyr), and increased 
side-chain conversion of Phe to downstream organic acid metabolites.  The 
enzyme PAH is responsible for the stereospecific, irreversible hydroxylation of L-
Phe to the non-essential amino acid tyrosine (Fig. 1.1; Pavon et al. 2006).  The 
enzyme assembles into a homotetramer forming a 165 kDa multimer of three 
domains: regulatory, catalytic and tetramerization domains.  Divalent iron (Fe2+)  
binds the catalytic domain of the enzyme to achieve full activity, and 
phosphorylation at serine 16 of the regulatory domain alters the conformation of 
the active site between open and closed forms (Richardson et al. 1993;  
Kaufman 1986).  PAH catalysis requires the cofactor tetrahydrobiopterin (BH4), 
which can exhibit pathway mutations in anabolic or recycling enzymes involved in 
its formation, which leads to a milder form of hyperphenylalanemia.  The genomic 
location of PAH maps to the 12th chromosome, region 12q22-12q24.1 in  
H. sapiens, and contains 13 exons (Lidsky et al. 1985). There are more than 500 
disease-causing mutations of the PAH gene reported on the PAH locus 
database, which present varying degrees of  disease phenotype (Williams et al. 
2008).  PKU is characterized by cognitive loss, white matter abnormalities, hypo- 
or demyelination of neuronal axons, and seizures caused by pathological 
phenylalanine levels.  Severe and irreversible mental retardation results in cases 
of untreated classical PKU (classical PKU characterized by blood Phe levels 
>1,200 µmol/L, hyperphenylalaninaemia or mild PKU Phe levels >600 and 
<1,200 µmol/L) (Lutz et al. 1982; Lutz et al. 1990). 
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Figure 1.1. Phenylalanine metabolism in mammals and the block in phenylketonuria.  
Hyperphenylalaninemia results from mutations in the PAH gene (99% of disease 
causing mutations) and enzymes responsible for BH4 synthesis and recycling (Erlandsen 
et al. 1999).  Phenylalanine hydroxylation to tyrosine is blocked, and phenylalanine 
undergoes side-chain conversion to keto-phenylpyruvate. 
 
1.2. Current treatment 
 
PKU patients are required to adhere to a protein-restricted diet, avoid foods high 
in phenylalanine content, and maintain lifelong dietary control.  However, in the 
meta-analysis by Enns et al. 2010, dietary treatment alone resulted in suboptimal 
outcomes for neurocognitive, psychosocial and nutritional factors in PKU 
patients.  Intellectual quotient and executive function were compromised in early-
treated adolescents exhibiting blood Phe variability within the recommended 
levels (target blood Phe 120-360 µmol/L; (NIH Consensus 2001).  Thus, 
metabolic fluctuations in Phe, or associated metabolites, appear to correlate  with 
cognitive development of PKU patients even in the case of dietary adherence  
(NIH Consensus 2001; Enns et al. 2010).  Some current research approaches to 
the treatment of hyperphenylalanemia seek to stabilize Phe levels through 
enzyme replacement therapy, cellular transplantation, or gene therapy.  Poly-
ethylene glycolated (PEG) phenylalanine ammonium lyase (PAL), which converts 
phenylalanine to the byproduct trans-cinnamate, has already progressed to 
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clinical trials.  However, the question of affordability and the feasibility of reaching 
the larger PKU population with enzyme replacement remain to be determined. 
A pharmacological approach to treatment with the drug sapropterin (Kuvan, 
BioMarin Corp.) has shown efficacy in the treatment of BH4-responsive PKU 
(Muntau et al. 2002).  Sapropterin therapy, as an alternative to dietary 
intervention alone, costs approximately $100,000 and $150,000 annually 
(estimate for the highest dosage of 20 mg/kg/day; (Harding 2010).  New dietary 
sources of protein isolated during cheese manufacturing have been shown to 
reduce brain and blood phenylalanine.  Glycomacropeptide, isolated from cheese 
whey, contains little or no phenylalanine, and a high threonine content (Ney et al. 
2008), which may reduce intestinal absorption and transport of Phe into the 
blood.  LNAA supplementation has been shown to improve levels of Phe in the 
blood, but this had limited efficacy for patients already adherent to a Phe 
restricted medical diet (Schindeler et al. 2007), and may result in negative 
nitrogen balance (Dotremont et al. 1995a).  Maintaining nutrient balance on a 
natural protein-restricted diet remains a challenge (Dokoupil et al. 2011), and 
non-adherence can result in cognitive declines, lethargy, depression, and 
problems with concentration.  PKU patients sometimes require individualized 
dietary regimes. 
 
Dietary adherent PKU patients experience suboptimal outcomes from dietary 
treatment alone resulting from fluctuating Phe levels (Anastasoaie et al. 2008), 
deficiency of certain vitamins and minerals (calcium, folate, thiamine, niacin, and 
vitamin B6 intake may be up to 60% below daily recommended intake levels 
(Koura et al. 2011), important long chain fatty acids (eg. docosahexanoic acid; 
(van Gool et al. 2000), and antioxidants.  Some PKU patients require vitamin B6 
and B12 supplementation (Hvas et al. 2006), and accompanying deficiency in 
folate can lead to moderate hyperhomocysteinaemia (Schulpis et al. 2002).  
Increased circulating homocysteine is a risk factor for coronary artery disease 
(CAD); folate supplementation is suggested for high-risk CAD patients as strong 
correlation between low folate and high homocysteine levels has been suggested 
(Lee et al. 2003).  Additionally, PKU patients have altered trace metal 
consumption including decreased selenium and zinc (Barretto et al. 2008), and 
increased iron and copper (Reilly et al. 1990).  Selenium is a trace metal required 
for selenoenzyme antioxidant species GPx 1 and 3-6, which protects cells from 
reactive nitrogen and oxygen species (Tinggi 2008).  Low levels of ubiquinone 
coQ10 (Colomé et al. 2003) and other lipophilic antioxidants may be responsible 
for observed higher lipid peroxidation seen in some PKU patients.  Carnitine and 
selenium supplementation in the diet of PKU patients for six months reverted 
oxidative damage and lipid peroxidation, normalized glutathione peroxidase 
activity, and revealed an inverse correlation between oxidative damage and 
carnitine levels (Sitta et al. 2011).  Whereas the brain is particularly sensitive to 
oxidative damage, and PKU patients remain at a high risk for brain pathology, it 
is important to prevent a pro-oxidant environment in order to reduce the risk of 
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neurological damage. PKU patients can still develop white matter lesions, as 
detected with magnetic resonance imaging (MRI), even with early detection and 
dietary treatment (Huttenlocher 2000). 
 
1.3. Neurological dysfunction 
 
Obligate heterozygous mothers of PKU patients can regulate Phe levels for their 
developing fetus in utero.  At birth, Phe levels increase rapidly.  If left 
unregulated, microcephaly, mental retardation, motor and behavioral 
disturbances may ensue.  The predominant pathology of hyperphenylalanemia 
occurs in the central nervous system (CNS), especially white matter in the deep 
and subcortical regions of the brain (Anderson et al. 2010).  White matter of the 
central nervous system is composed of the white fatty substance myelin, 
composed of millions of myelinated axons, which are responsible for signal 
transmission.  Neuropathological features in the CNS of untreated PKU include: 
hypomyelination or demyelination, lesions, reactive astrogliosis, and reduced 
Purkinje (GABAergic neurons) cell dendritic arborization (Dyer 1999).  The 
pathogenesis of PKU, although not completely understood (de Groot et al. 2010), 
at a minimum, results from the consequences of abnormally high blood and 
cerebral phenylalanine and downstream effects on the transport of other large 
neutral amino acids, LNAA (Fig. 1.2).     
 
The importance of the blood brain barrier (BBB) in the biochemical regulation of 
LNAAs has been implicated in the neuropathology of the disease by magnetic 
resonance spectroscopy (MRS), which permits in vivo cerebral Phe 
measurements.  MRS studies enable correlation between cerebral levels of Phe 
and the degree of cognitive impairment and growth in patients (van Spronsen et 
al. 2009).  Studies by Anderson et al. correlated concurrent and lifetime Phe to 
white matter abnormalities (based on the median Phe level over 12 months, r2 = 
0.61 (Anderson et al. 2007; Anderson et al. 2010).  High Phe levels have also 
been shown to inhibit selected enzymes, including tyrosine and tryptophan 
hydroxylases, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR; Shefer et al. 
2000a), and pyruvate kinase.   
 
Current treatment strategies for PKU are targeted to curtail Phe accumulation in 
the blood and brain and its associated pathomechanisms.  Among various 
systems of amino acid transporters identified (system A transporter (SAT), 
ASCT, y+, x-c, and b
0,+; see Fig. 1.5), transport of Phe and other LNAAs takes 
place via a system of L-type amino acid transporters (Babu et al. 2003). 
 
1.4. L-type amino acid transporter, LAT1 
 
Four mammalian LATs (1-4) comprise the system of transporters in mammals 
responsible for the movement of LNAAs.  System L transporters are Na+ and Cl- 
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independent, heterodimeric, transmembrane proteins responsible for the 
basolateral movement of amino acids.  Functional expression requires 
association with the type II glycoprotein 4F2 heavy chain, 4F2hc/CD98 (Rossier 
et al. 1999).  The two distinct genes corresponding to the heavy and light chain 
(LAT1) units are the solute carrier SLC2A2 and SLC7A5, respectively (Verrey et 
al. 2004).  LATs are expressed with varying tissue specificity and substrate 
affinity (Table 1.1).  Phenylalanine and eight other LNAAs traverse the BBB with 
high affinity (Km = 12 to 50 µM, His, Phe, Leu, Met, Trp, Ile, Tyr, Val; Gln with 2 
orders of magnitude lower affinity Km = 1.6 mM) via LAT1 facilitated amino acid 
exchange (Fig. 1.2, Table 1.1).  LAT1 has widely expressed mRNA levels.  LAT-
2 exhibits broad LNAA usage and high affinity (Km = 30 to 50 µM) for Tyr, Phe, 
Trp, Thr, Asn, Ile, Cys, Ser, Leu, Val, and Gln), lower affinity (180 to 300 µM) for 
His, Ala, Met, and Gly, and is primarily expressed in the small intestine, kidney, 
brain and placenta (Segawa et al. 1999).  The affinity of LAT1-4 for LNAAs is 
high in comparison to blood concentrations (Km value < 200 μM) guaranteeing 
their saturation at normophysiological blood amino acid levels.  LAT1 and LAT2 
(the latter an isoform of LAT1) are both expressed in the brain and facilitate 
tissue uptake from the blood capillaries; system L is crucial to cellular 
homeostasis and transport of neutral amino acids.   
 
Table 1.1.  
System L-type amino acid transporters 
 
Transporter Tissue 
Expression 
Amino Acid 
Selectivity 
Selected 
Kms (µM) 
Citations 
LAT-1 Brain, 
spleen, 
placenta, 
testis, fetal 
liver 
Large neutrals: 
F,Y,W,M,H,L,I,V 
Phe 14 
Leu 20 
Tyr 28 
Trp 21 
Met 20 
His 12 
(Kanai et 
al. 1998) 
(Yanagida 
et al. 
2001) 
LAT-2 Brain, 
small 
intestine, 
kidney, 
placenta 
Large and small 
neutrals: 
F,Y,W,L,I,V,T,N,C,S,Q 
(M,H,G,A) 
Phe 45 
Leu 119 
Tyr 36 
Trp 58 
Met 204 
His 181 
(Segawa 
et al. 
1999) 
 
LAT-3 Liver, 
pancreas, 
skeletal 
muscle 
Amino acids (and 
amino acid alcohols): 
F,L,I,V 
Phe 6* 
Leu 8* 
(Babu et 
al. 2003) 
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Table 1.1 (continued) 
Transporter Tissue 
Expression 
Amino Acid 
Selectivity 
Selected 
Kms (µM) 
Citations 
LAT-4 Kidney, 
placenta, 
leukocytes 
Large neutrals: 
F,L,I,M 
Phe 178* 
Leu 103* 
(Bodoy et 
al. 2005) 
Mammalian LATs:  Tissues in which the transporters are expressed, amino acids 
transported by each LAT, and the affinity of the transporter for selected amino acids are 
summarized.  LAT2 is an isoform of LAT1, and LAT4 is an isoform of LAT3.  The lower 
affinity amino acids transported by LAT2 are shown in parentheses.  LAT3 and LAT4 
have both high and low affinity forms (regulated by phosphorylation). *High affinity Km 
listed for LAT3 and LAT4.  Km describes the concentration at half-maximal velocity in the 
absence of competitors (measured in Xenopus oocytes). 
 
Supraphysiological levels of Phe in PKU are predicted to saturate the LAT 
transporters and competitively exclude other LNAAs from transport.  Cerebral 
protein synthesis is dependent upon  concentrations of essential amino acids 
(Nishihira et al. 1993), normal transport and metabolic machinery, and multiple 
other functions critical for brain development.  Transport inhibition of LNAAs 
during hyperphenylalaninemia may influence the following: reduced cerebral 
protein synthesis due to abnormal LNAA homeostasis, neurotransmitter 
synthesis (dopamine, serotonin), and proteins necessary for axonal myelination, 
such as myelin basic protein (MBP) ( Antoshechkin et al. 1991; Shefer et al. 
2000b; Joachim Pietz et al. 2003; Hörster et al. 2006; Ogawa et al. 2006).  
  
Transport competition during hyperphenylalaninemia occurs at the blood brain 
barrier and gut endothelium, where the large neutral amino acid transporters 
selectively bind and transport amino acids transcellularly.  The Michaelis-Menten 
constant (Km) for LAT1, defined as the ½ maximal transport saturation, 
represents the affinity of the LAT1 system for amino acid transport.  Phe is 
transported with high affinity on all four LATs.  LAT1 has a Km for phenylalanine 
of 11 µmol/L (measured in rat brain in situ), and with blood phenylalanine levels 
in classical phenylketonuria fluctuating at or above 1,200 µmol/L, Phe can easily 
oversaturate the LAT system and exclude other LNAAs through mass action 
alone (Fig. 1.2; Kanai et al. 1998).  Certain non-physiological amino acids, 
NPAAs, have proven effective at competing with Phe for LAT1 transport. 
 
7 
 
 
 
Figure 1.2. LNAA trafficking on LAT1 in PKU: Schematic diagram of the LAT1 
transporter at the blood brain barrier. Accumulation of supraphysiological levels of amino 
acids in PKU are shown with downstream outcomes related to disrupted LAT1 transport:  
monoamine neurotransmitters (serotonin, dopamine), the brain’s primary methyl donor, 
S-adenosylmethionine, and histamine.  High levels of phenylalanine and leucine, 
respectively, contribute to depletion of histidine, methionine, tryptophan (Trp), and 
tyrosine (Tyr) in the brain due to competitive exclusion via LAT1 oversaturation at the 
blood brain barrier.  Lower histidine decarboxylation in the brain may alter histamine 
neurotransmission from the tuberomammillary nucleus to other brain regions 
(immunological function when released from mast cells which leads to vasodilation and 
permeability; however, mast cells are less numerous in the brain than other tissues 
(Brown et al. 2001).  Altered synthesis of monoamine neurotransmitters serotonin and 
dopamine result from depletion of Trp and Tyr (Fig. 1.3). Adapted from (Strauss et al. 
2010). 
 
Figure 1.3. Dopamine (DA) and Serotonin (5-HT) synthesis and metabolism. 
Abbreviations: L-dihydroxyphenylalanine (L-DOPA); 5-hydroxytryptophan (5-HTP); 3,4-
dihydroxyphenylacetic acid (DOPAC); homovanillic acid (HVA, DA turnover is measured 
as the ratio of (DOPAC + HVA)/DA; 3- methoxytyramine (3-MT, a DA metabolite 
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released into the synaptic cleft, DA release into the synaptic cleft, 3-MT/DA); 5-
hydroxyindoleacetic acid (5-HIAA; serotonin turnover measured as 5- HIAA/5-HT).   
 
1.5. Non-physiological amino acids, NPAAs 
 
Competition between LNAAs for transport into rat brain was documented more 
than 60 years ago  (Christensen et al. 1948), and competition between Phe and 
Leu for uptake across the BBB has been confirmed in PKU patients at differing 
Phe levels (Knudsen et al. 1995).  Pietz and coworkers (1999) were the first to 
demonstrate that LNAA supplementation in diet could decrease Phe levels (Pietz 
et al. 1999).  Others (Matalon et al. 2006; Michals-Matalon et al. 2007) have 
successfully modified this diet with improved outcomes in PKU patients, yet the 
long term use of these diets may be thwarted  by negative nitrogen balance 
(Dotremont et al. 1995; van Spronsen et al. 2010). These observations suggest 
that therapeutic competition for amino acid transport into the brain of individuals 
with aminoacidurias such as PKU may be feasible, as has been suggested by 
others ( McKean et al. 1968; Tews et al. 1986; Tews et al. 1990; Tews et al. 
1991).  Nonetheless, a systematic study of this approach has not been 
presented.  Zinnanti and coworkers (2009) recently verified the feasibility of this 
therapeutic approach employing dietary supplementation with the NPAA 
norleucine (NL) in mice with maple syrup urine disease (Fig. 1.2, 1.4.A).  NL 
supplementation in this model (in which branched-chain amino acids Leu, Ile and 
Val accumulate) extended lifespan while improving both brain biochemistry and 
neurobehavioral outcomes.  The work of Zinnanti extended earlier reports by 
Tews and Harper (1986), who showed that NL supplementation effectively 
lowered Phe level in rat brain.  Similarly, Ennis and coworkers (1994) 
demonstrated that another NPAA, alpha-aminoisobutyrate (AIB; Fig. 1.4.C) could 
compete with Phe for transport via LAT1.  LAT1 also traffics α-methyl amino 
acids such as α-methylphenylalanine, α-methyltyrosine, and 3-O-methyldopa, 
which were shown to block the uptake of Phe (Uchino et al. 2002).  Methyl-
aminoisobutyric acid, MAIB (Fig. 1.4.D), is specific for the small neutral amino 
acid, alanine-preferring system A transporter (SAT), which is a sodium-
dependent carrier that has some affinity for LNAAs such as Phe (Hargreaves and 
Pardridge 1988; Grewer and Grabsch 2004; Rutter et al. 2007).  Finally, NB (Fig. 
1.4.B) represents the prototypical NPAA inhibitor of the LAT 1-4 system (Table 
1.1), yet it has never been examined systematically as a therapeutic regimen in 
any mammalian system or animal model. 
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Figure 1.4. Non-physiological amino acids (NPAA): A, norleucine (NL); B, 2-
aminonorbornane (NB); C, 2-aminoisobutyric acid (AIB); D, N-methyl-2-aminoisobutyric 
acid (MAIB). MAIB is a selective inhibitor of the A-system (see above). 
 
Figure 1.5. Amino acid transport systems at the blood-brain barrier (BBB).  Transport 
system nomenclature uses one letter amino acid codes: A, alanine preferring, ASC, 
alanine-serine-cysteine preferring, and L1, leucine preferring.  Amino acids transported 
are listed beside each transport system, and non-physiological amino acid competitors 
are shown in red (norbornane (NB) is also called 2-aminobicyclo-(2,1,1)-heptane-2-
carboxylic acid (BCH)).  Gray shading signifies Na+-dependent transport, and white 
boxes denote facilitative amino acid exchange. 
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1.6. The Pahenu2  mouse 
 
To determine whether NPAA inhibitors of the LAT1 transporter will reduce 
cerebral phenylalanine, and how LAT1 inhibition might subsequently alter 
transport of other LNAAs, NPAAs will be administered to the Pahenu2 mouse.  The 
Pahenu2 mouse harbors a single nucleotide polymorphism converting a highly 
conserved phenylalanine to serine (F263S) within the enzyme catalytic domain 
(McDonald and Charlton 1997). Although PAH mRNA and protein are detectable 
in the liver, the enzyme is inactive, and homozygous animals are consistently 
hyperphenylalaninemic with cognitive and growth retardation ( McDonald et al. 
1990; UK PubMed Central 1995; Zagreda et al. 1999).  Cerebral protein 
synthesis is decreased in this model (Smith et al. 2000), as are neurotransmitter 
concentrations in brain extracts (Pascucci et al. 2002; Joseph et al. 2003).  
Additionally, decreased content of branched chain amino acids (Val, Ile, Leu) has 
been documented in the brain of hyperphenylalaninemic animal models created 
by administration of phenylalanine metabolism inhibitors (Puglisis-Allegra et al. 
2000; Pascucci et al. 2002).  The Pahenu2 mouse is the disease model of PKU 
most relevant to the human disorder and therefore most suitable for preclinical 
evaluation of dietary LAT inhibitors to assess efficacy.   
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2. Objective  
 
In this thesis project, the objective was to use non-physiological amino acids 
(NPAAs) to selectively restrict Phe transport into cerebral tissue.  The selected 
amino acids used in this study (NL, NB, AIB, and MAIB) are known to, or 
predicted to, inhibit the different LATs.  The main objective of this work is to 
provide preclinical data leading to translational outcomes that will provide a new 
treatment approach to PKU. The hypothesis is that a particular combination of 
NPAA inhibitors of the LAT-1 system can be found to selectively preclude Phe 
from the brain.  Ideally, this dosage would have minimal impact on the levels of 
other LNAAs in the brain.  Such a treatment approach could have important 
clinical relevance for adolescents and adults that have difficulty adhering to a 
Phe-restricted diet.  Blocking Phe transport could also improve suboptimal 
outcomes seen in some patients treated with the PKU diet alone. 
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3. Materials and methods 
 
3.1. Husbandry and subject number  
 
To breed offspring for the experiment, polygamous breeder pairs were 
established with male Pah-/- and female Pah+/- subjects.  Offspring were 
genotyped with tail clip extracted DNA performed at weaning (20 days of life).  
This was followed by PCR and restriction endonuclease digestion with BsmAl, 
and then visualized by agarose gel (4%) electrophoresis, as described (Zagreda 
et al. 1999).  Since amino acid levels are similar between Pah+/+ and Pah+/- 
subjects, Pah+/- subjects were used as controls, obviating the need for additional 
husbandry to generate Pah+/+ subjects. This is consistent with our laboratory’s 
adherence to the best practices of animal usage suggested by the Association 
for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and the 
objective of replacing, reducing and refining the use of animals in biomedical 
research.  An n=5 sample size facilitated simple parametric statistical analysis (t-
test, ANOVA).  This sample size was based on power calculations utilized in an 
unrelated study of MSUD mice in which hepatocyte transplantation was the study 
parameter.  In that work, an n=5 sample size (hepatocyte-transplanted MSUD 
mice vs. PBS-transplanted MSUD mice) enabled us to detect a 20% reduction in 
the metabolic parameter alloisoleucine (pathognomonic for MSUD) with a 
significance of p<0.05.  Accordingly, this number of subjects was adopted in the 
current study.  (Protocol approval for studies with vertebrate animals IACUC 
L0214) 
 
3.2. NPAA administration 
 
NPAAs were administered to mice in their food to assess their potential use as 
interventions in PKU.  Dietary compounds included 5% α-aminoisobutyric acid 
(AIB), 5% DL-norleucine (NL), 0.5% norbornane (2-aminobicyclo(2,2,1)heptane-
2-carboxylic acid, NB), 3% α-methyl-aminoisobutyric acid (MAIB) (Sigma 
Aldrich), and control chow (2018 Teklad Global Rodent Chow, 18% protein, and 
extruded sterilizable 2018X).  We employed 5% (w/w) NL and AIB based upon 
the previous report of Zinnanti et al (2009) employing MSUD mice.  The expense 
of NB (~$350/g) prohibited its use at 5%; accordingly, we chose 0.5% w/w (a 
serendipitous choice).  Two separate feeding experiments were performed.  The 
first experiment with NL, NB and AIB used regular 18% mouse chow from 
Tekklad (18R), and the second with MAIB used sterilizable, extruded 18% protein 
chow.  Chow was made in batches of 300 g.  18R was made with 300 mL of 
filtered water and mixed with drug and dehydrated 24 hours at 46°C.  18X chow 
was made with 500 liters of autoclaved water and dehydrated 20-24 hours at 
46°C.  The compounds themselves were not autoclaved.  Dietary intervention 
was instituted at 3.5 weeks of age (post weaning and genotyping) and 
maintained for 3 weeks. Animals were housed under a 12 hour light/dark cycle 
13 
 
with ad lib access to food and water.  Mouse weights were recorded three times 
weekly, and food consumption calculated weekly.  Blood spots were collected on 
Day 0 via saphenous vein puncture and capillary tube collection and spotted onto 
newborn screening blood spot cards (GE Healthcare) stored at -20°C.  These 
were collected with the intention of looking at temporal changes in amino acid 
levels in blood without sacrificing the animal.  At week three sacrifice, terminal 
blood spots, brain halves, and sera were collected into 1.5 mL tubes.  Brain 
halves were flash-frozen with liquid nitrogen and stored at -80°C. 
 
3.3. High performance liquid chromatography, HPLC 
 
Catecholamine metabolites in Pah-/- and Pah+/- mouse ½-brain (homogenized 
with a 1:5 dilution of ice cold 0.1M perchloric acid, dithioerythritol, and 
diethylentriamine pentaacetic acid) were quantified by reverse-phase HPLC with 
electrochemical detection.  Dihydroxyphenylacetic acid (DOPAC), 3-
methoxytyramine (3-MT), homovanillic acid (HVA), dopamine (DA), 5-
hydroxyindole-3-acetic acid (5-HIAA), 3-O-methyldopa (3-OMD), and serotonin 
(5-HT) represent the key monoamines for our NPAA interventions (CoulArray) 
(Ogburn et al. 2006); HPLC and LC-MS analysis Dr. T. Bottiglieri, Baylor 
University Medical Center, Dallas, TX).   
 
3.4. Liquid chromatography tandem mass spectrometry 
 
LNAAs in serum and ½-brain were quantified using liquid chromatography-mass 
spectrometry (LC-MS) with electrochemical detection.  Standards of S-
adenosylmethionine (SAMe), S-adenosylhomocysteine (SAH), betaine (Bet), 
choline (Cho), methionine (Met), tryptophan (Trp), and tyrosine (Tyr) (Sigma).  
Stable isotope internal standards included betaine-d3 (BET-D3), choline-d4 
(CHO-D4), methionine-d3 (MET-D3), tryptophan-d3 (TRP-D3), and tyrosine-d7 
(TYR-D7) purchased from Cambridge Isotope Laboratories or CDN Isotopes 
INC.  Stable isotope standards facilitated very accurate quantitation.  
Heptafluorobutyric acid and formic acid were purchased from Fluka.  Ammonium 
acetate was purchased from Sigma, and Optima LC/MS methanol from Fisher 
Chemicals.  The HPLC system consisted of a complete Shimadzu Prominence 
HPLC system with a SCL-10Avp controller.  The instrument used for analysis 
was an ABI 4000 QTRAP LC/MS/MS system.  Three groups of stock standards 
were prepared in 0.1 M HCL at a concentration of 1 mM and fourth group was 
prepared in 0.1 M HCL at a concentration of 4 mM.  All stable isotope internal 
standards were prepared in 0.1 M HCL at a concentration of 1 mmol/L and stored 
at -80ºC.  All four calibration standard groups were stored at -80C until needed. 
From these stock solutions a five level standard curve was prepared by diluting 
stock solutions in Type 1 water.  Tissue samples that were previously 
deproteinized 1:5 with ice-cold 0.1 M PCA were thawed and spun.  Samples 
were prepared by the addition of 150 µL mobile phase A containing 20 µmol/L 
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2H3-SAMe to 50 µL of standard or plasma and mixed by vortex.  150 µL of 
sample mixture was added to a Microcon YM-10, 10 kDa NMWL microcentrifugal 
filter unit and centrifuged for 15 min at 14800 x g at 4ºC.  Sample filtrate was 
removed and transferred to autosampler plate for analysis.  5 µl were injected 
into the LC-MS system, described above.  Solvents for HPLC were: A, 4mM 
ammonium acetate, 0.1% formic acid, 0.1% heptafluorobutyric acid (pH=2.5); B 
100% methanol and 0.1% formic acid.  All analytes were separated on a 250 x 
2.0 mm EZ-faast analytical column (Phenomenex) maintained at 33°C at a flow 
rate of 250 μL/min, with a binary gradient and a total run time of 12 min. The 
initial gradient condition was 75% A: 25% B and was ramped in a linear fashion 
to 100% B in 6 min and held constant for 1 min.  At 7.1 min the mobile phase 
was reset to initial conditions for 7 minutes.  The flow from the column was 
delivered to the electrospray ionization (ESI) source from the period of 3 to 8 min; 
otherwise the flow was diverted to waste.  The compounds were detected by 
multiple reaction monitoring (MRM) using positive ESI with a dwell time of 30 ms.  
The curtain gas was set at 15 L/min, and source gas 1 and 2 were set at 60 
L/min.  The heater was set to 700ºC with an ionspray voltage of 5,000 V and 
collision gas (nitrogen) was set at 3.5 x 10-5 Torr.  All data were collected using 
Analyst software version 1.4.2 (Slocum et al. 1991; Puglisis-Allegra et al. 2000; 
Ogburn et al. 2006). 
 
3.5. Statistical analysis 
 
Metabolite data was grouped with respect to genotype (Pah+/-, Pah-/-) in order to 
correlate NPAA effects under normo- and hyperphenylalaninemic conditions. 
Since we employed a column statistical approach (ANOVA with Tukey post-hoc), 
grouping by genotype significantly reduced data analysis.  Analysis was 
performed with Graphpad Prism V5. 
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4. Results 
 
4.1. Health and food consumption 
 
As a simple gauge of animal well-being and to verify intake of the drug, food 
consumption, and body weights were recorded.  Food and water consumption, 
and body weights, did not differ significantly with respect to control cohorts as a 
function of treatment intervention (Table 4.1), except 5% NL.  One subject died, 
and another was near death at sacrifice for NL.  There were no outward 
phenotypic differences for subjects consuming NB, AIB or MAIB, as estimated 
from visual health inspections.  Conversely, subjects consuming 5% NL 
displayed some motor impairment, but movement anomalies were not yet 
quantified.   
 
Table 4.1. Health and food consumption 
Diet, genotype, average weight gain (3 week duration), and  
food consumption (Week1, 2, 3). 
Diet Genotype 
Ave. 
weight 
gain (g) Wk 1  Wk 2  Wk 3  
18% 
protein Het (n=7) 3.83 3.57 3.16 3.12 
 
Mut (n=5) 2.84 3.94 3.91 3.49 
AIB 5% Het (n=5) 4.72 2.55 2.98 3.16 
 
Mut (n=5) 2.16 1.86 1.64 2.28 
NL 5% Het (n=5) 1.64 1.95 2.74 no data 
 
Mut (n=4) -0.43 2.06 2.35 2.57* 
NB 0.5% Het (n=5) 5.28 2.99 3.06 3.05 
 
Mut (n=5) 6.38 2.51 2.89 2.90 
18X 
protein Het (n=5) 11.96 2.41 3.69 3.03 
 
Mut (n=5) 4.88 2.04 3.49 2.44 
MAIB 3% Het (n=4) 9.05 1.93 2.75 2.63 
 
Mut (n=6) 8.08 1.84 2.57 3.71 
 
4.2.  Amino acids in brain 
 
Amino acid levels in the brain were measured to determine the effectiveness of 
NPAA LAT1 competitors to reduce Phe, as well as to gauge outcomes on other 
LNAAs.  NL, NB, and MAIB feeding significantly lowered brain Phe levels in Pah-
/- subjects, with NL displaying the largest reduction (even in Pah+/- subjects); 
conversely, 5% AIB was not effective at reducing brain Phe.  Although none of 
the dietary interventions altered Trp levels (an intriguing observation in view of 
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catecholamine disturbances; see Fig. 4.3.a), pronounced effects on Tyr, BCAA 
and Met were seen (Fig. 4.1.a,b).  Tyr levels were significantly decreased in both 
genotypes during NL and NB interventions, while these diets had a more 
pronounced effect on BCAAs in Pah+/- mice (although NL did reduce BCAA levels 
in Pah-/- subjects).  MAIB decreased Phe and Tyr levels significantly in the Pah-/- 
subjects (p<0.005 and p<0.05 respectively), and did not significantly alter total 
BCAA (sum of Val, Leu, and Ile).  NL, NB, and AIB decreased Met levels in Pah+/-
subjects, and both NB and AIB feeding resulted in decreased Met levels in Pah-/- 
subjects.  MAIB did not alter Met levels (Fig. 4.1.b).  NL intervention significantly 
reduced SAMe, in both genotypes.  We extended SAMe studies by measuring 
the associated sulfhydryl analogue, S-adenosylhomocysteine (SAH; see bottom 
right quadrant, Fig. 4.2.), in which the effects of NL on SAMe were reproduced 
with respect to SAH.  As for SAMe, SAH levels were not different by genotype in 
control cohorts (no NPAA).  Moreover, we found a hypercorrection of SAH levels 
with NB feeding (Fig. 4.2.a; p<0.05 with respect to control).  Although no 
significant difference in SAMe was observed with MAIB, brain SAH levels were 
decreased (p<0.001).   
 
We next performed t-test analyses of each NPAA diet as a function of genotype 
(not shown in Fig. 4.1.a).  These analyses revealed significant differences 
between Pah+/- and Pah-/- subjects as follows: Phe (control and all diets, as 
expected); Tyr, only AIB and NB; Trp and BCAAs, only in control; Met, control 
and AIB; SAMe and SAH (Fig. 4.2.a,b), only AIB, and SAH only for MAIB.  Of 
interest (Fig. 4.1.a) was the observation of a lack of a significant difference for 
Tyr with respect to genotype (in the absence of dietary intervention), perhaps 
explaining why dopamine anomalies are less pronounced than serotonin defects 
in Pah-/- subjects 
17 
 
T 
(7
)
T 
(5
) 
T 
(5
)
T 
(5
)
M
 (5
)
M
 (5
)
M
 (4
) 
M
 (5
) 
0
200
400
600
800
1000
Control
5% AIB
5% NL
0.5% NB
*
*
*
Genotype (n)
P
h
e
n
y
la
la
n
in
e
 (
n
m
o
l/
g
)
T 
(7
)
T 
(5
) 
T 
(5
)
T 
(5
)
M
 (5
)
M
 (5
)
M
 (4
) 
M
 (5
) 
0
100
200
300
*
*
*
*
Genotype (n)
T
y
ro
s
in
e
 (
n
m
o
l/
g
)
T 
(7
)
T 
(5
) 
T 
(5
)
T 
(5
)
M
 (5
)
M
 (5
)
M
 (4
) 
M
 (5
) 
0
5
10
15
20
25
Genotype (n)
T
ry
p
to
p
h
a
n
 (
n
m
o
l/
g
)
T 
(7
)
T 
(5
) 
T 
(5
)
T 
(5
)
M
 (5
)
M
 (5
)
M
 (4
) 
M
 (5
)
0
100
200
300
400
*
*
*
Genotype (n)
B
C
A
A
 (
n
m
o
l/
g
)
T 
(7
)
T 
(5
) 
T 
(5
)
T 
(5
)
M
 (5
)
M
 (5
)
M
 (4
) 
M
 (5
)
0
20
40
60
80
* * *
*
*
Genotype (n)
M
e
th
io
n
in
e
 (
n
m
o
l/
g
)
T 
(7
)
T 
(5
) 
T 
(5
)
T 
(5
)
M
 (5
)
M
 (5
)
M
 (4
) 
M
 (5
) 
0
5
10
15
20
25
*
*
Genotype (n)
S
A
M
e
 (
n
m
o
l/
g
)
 
Figure 4.1.a. Brain LNAAs and SAMe as a function of diet (NL, NB, AIB) and genotype 
(T, Pah+/; M, Pah-/-).  Brain LNAA levels, and that of the methionine derivative S-
adenosylmethionine (SAMe), are shown in Fig. 4.1.  SAMe measurements were 
proposed to assess possible downstream effects if alterations of Met levels were 
encountered during NPAA consumption (see below).  Moreover, for ease of 
presentation, values were summed for Ile, Val and Leu (branched-chain amino acids 
(BCAAs)).  Statistical analysis (one way ANOVA with Tukey post-hoc) compared cohorts 
with and without NPAAs, and within genotype only (*p<0.05 compared to control). 
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Figure 4.1.b. Brain LNAA and SAMe as a function of diet (MAIB) and genotype (T, 
Pah+/; M, Pah-/-). Evaluation of dietary intervention with 3% MAIB in Pahenu2 mice.  
Statistical analysis (unpaired two-tail t-test) compared cohorts with and without MAIB, 
and within genotype only (*p<0.05 compared to control).   
 
4.3. Amino acids in sera 
 
Quantification of amino acids in sera provides an indication of possible LAT 
competition and nutrient absorption in the gut.  Analyses of amino acids in sera 
demonstrated fewer significant differences and more variability than those in 
brain (Fig. 4.2) (potentially associated with smaller subject numbers for NL).  
Further, small sera volumes did not enable us to measure SAMe and SAH.  AIB 
intervention had a significant impact on blood Met (consistent with brain results) 
and Trp (Fig. 4.2.a).  None of the dietary interventions significantly altered blood 
Phe, perhaps suggesting a lack of effect on Phe uptake in the gut.  We again 
performed t-test analyses for each intervention as a function of genotype, and 
observed significant differences between Pah+/- and Pah-/- subjects as follows: 
Phe (control and all diets, as expected); Tyr, both control and NB feeding; 
BCAAs, control only.  There were no significant differences observed for Trp and 
Met.  The trend for sera BCAA was toward higher levels in Pah-/- subjects, which 
could potentially reflect catabolism associated with muscle proteolysis and BCAA 
release.   
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Figure 4.2.a Sera LNAAs and SAH as a function of diet (NL, NB, AIB) and genotype (T, 
Pah+/; M, Pah-/-).  See Fig. 4.1.a legend for abbreviations and statistical analysis.  Note: 
brain SAH shown in the bottom right quadrant (pertinent to Fig. 4.1.a).    
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Figure 4.2.b. Sera LNAAs and SAH as a function of diet (MAIB) and genotype (T, 
Pah+/; M, Pah-/-).  See Fig. 4.1.b legend for abbreviations and statistical analysis.  Note: 
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brain SAH shown in the bottom right quadrant (pertinent to Fig. 4.1.b).  No significant 
alteration of serum LNAAs occurred with MAIB feeding.  
 
4.4. Catecholamine levels in brain 
 
Determining deficiency or restoration of serotonin, 5-HT and/or dopamine, DA, 
precursors and turnover in the brain signifies important effects of NPAA 
administration on locomotor and social function in the mice.  Catecholamine 
analyses with respect to dietary intervention are shown in Fig. 4.3.a,b.  There 
were no differences for DOPAC, HVA and DA release (quantified as the 3-
MT/DA ratio with respect to AIB, NL, or NB for either genotype.  For MAIB, these, 
as well as 3-MT, were decreased in the brain for both genotypes.  MAIB feeding 
reduced metabolites in the DA and 5-HT systems.  In the Pah-/-mouse, the 
turnover of DA and 5-HT were reduced, and in the Pah+/- mouse DA and 5-HT 
themselves were reduced.  AIB feeding did not alter any metabolite with respect 
to control cohorts (Fig. 4.3.a).  NL feeding did not significantly alter the DA 
system, but did impact 5-HT and 5-HIAA levels in Pah+/- subjects.  NB feeding 
markedly affected both DA and 5-HT systems (Fig. 4.3.a), with significant 
decreases of DA in both genotypes, and 3-MT in Pah-/- subjects.  As well, NB 
significantly decreased 5-HT in Pah+/- and Pah-/- subjects.  NB feeding did not 
alter 5-HIAA levels in either genotype, while the turnover of both DA and 5-HT 
was markedly increased in both Pah+/- and Pah-/- subjects. Again, t-test analyses 
for each dietary intervention as a function of genotype were carried out, which 
revealed significant differences between Pah+/- and Pah-/- subjects as follows: 
DA, control and all diets except NL (this was also the case for 5-HT turnover); 3-
MT, all diets but not the control cohort; 5-HT and 5-HIAA, all groups and 
interventions; and DA turnover, only for NL and NB.  Overall, these findings 
agree with previous analyses of PKU mice, with the exception of a lack of 
significant difference in the control cohort for DA turnover. 
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Figure 4.3.a. Brain catecholamines as a function of diet (NL, NB, AIB) and genotype 
(T, Pah+/; M, Pah-/-).  See Fig. 4.1.a for abbreviations.  Statistical analysis performed as 
for Figs. 4.1.a & 4.2.a (* p<0.05). 
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Figure 4.3.b. Brain catecholamines as a function of diet (MAIB) and genotype (T, 
Pah+/; M, Pah-/-).  Statistical analysis performed as for Figs. 4.1.b & 4.2.b (* p<0.05).   
 
4.5. NPAA levels in brain and blood  
 
NPAA consumption does not guarantee absorption or transport.  Ideally, 
systemic and repetitive measurement would provide the best measure of the 
pharmacokinetics and dose-response to validate the Phe-reducing capacity of 
our interventions.  To this end, both NL and NB have been quantified in terminal 
samples of sera and brain using an HPLC-based methodology.   In five subjects, 
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the sera NL concentration was 3.11 + 0.41 mM (SD; range 2.57-4.75) while that 
in brain was 822 + 27 nmol/g tissue (assuming a tissue density approximating 
water, ~0.82 µM).  For NB, the sera concentration was 0.21 + 0.11 mM (SD; 
range 0.08-0.31, n=4), while that in brain was 276 + 104 nmol/g tissue (n=9), or 
~0.28 µM.  These values indicate both absorption and uptake into brain, and 
roughly reflect the 10-fold difference in level of application (5% NL, 0.5% NB).  
An HPLC and tandem mass spectrometry-based method to quantify both AIB 
and MAIB in tissue extracts and blood is in progress. 
 
4.6. Effect of NL feeding on blood chemistries  
 
Subjects (Pah+/-) were supplemented with 5% NL (n=7) or standard chow (n=6) 
for 3 weeks, after which sera was isolated for blood chemistries.  The latter 
included glucose, blood urea nitrogen (BUN), creatinine, total protein, albumin, 
phosphorus, Na+, Cl-, K+, total CO2, cholesterol, triglycerides, Ca
++, total bilirubin, 
alkaline phosphatase (ALP), alanine aminotransferase, and gamma-
glutamyltransferase.  No significant differences were observed between cohorts, 
with two exceptions: BUN (5.43 + 0.30 mg/dL (+NL) vs. 3.83 + 0.17 (no NL) 
(p=0.001; two-tailed t-test); and ALP (41.6 + 4.0 U/L (+ NL) vs. 57.7 + 2.3 (no NL) 
(p=0.0065).  It is unclear why NL supplementation would depress ALP, since 
other hepatic enzymes were normal.  On the other hand, it appears that NL is 
contributing to an increased BUN via transamination, and thus careful monitoring 
of blood chemistries will be prudent for future studies. This observation suggests 
that NL is at least somewhat metabolizable in the body, perhaps in the liver, but 
also potentially by intestinal bacteria (Der Garabedian and Vermeersch 1987). 
   
5. Discussion 
 
These interventional studies represent the first application of NL and AIB in an 
model of PKU, and the first in vivo application of NB in any mammal.  MAIB has 
been used to study transport of amino acids across the blood-nerve barrier in 
rats, where MAIB was found to have no inhibitory effect on blood to nerve influx 
of Phe using intravenous injection (Wadhwani et al. 1990).  The Phe-reducing 
capacity of both NL, NB (Fig. 4.1.a) and MAIB (Fig. 4.1.b) provides proof-of-
principle to support further characterization of these compounds.  Unfortunately, 
neither species selectively acted on Phe (at the concentrations employed), with 
significant effects on other LNAAs and catecholamines.  NL did, however, 
normalize DA levels and 5-HT turnover between genotypes, pointing to a positive 
effect on catecholamines.  Despite its inability to lower Phe, AIB warrants further 
evaluation at higher concentrations, especially since its effects on other 
biomarkers (LNAAs, catecholamines, etc.) were much milder than those of NL 
and NB.   
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A novel finding in these studies was the effect of MAIB on LNAA transport.  MAIB 
is purported to be a specific A-system inhibitor (Fig. 1.5), yet it significantly 
reduced Phe and other LNAAs, and had a pronounced effect on the dopamine 
system in both genotypes.  Overall the data suggests that MAIB may be the 
target compound with the most potential to reduce Phe with the least effect on 
other LNAAs in the brain.  Indeed, feeding of 3% MAIB had no effect on Met and 
Trp, and the mildest effect on Tyr of any of the treatments attempted (-1:30 , 
56:55 , 27:86, 14:25, percent decrease Phe:Tyr for 5% AIB, 5% NL, 0.5% NB, 
and 3% MAIB respectively as compared with control diet (Table 5.1).  Data is 
currently being collected to confirm that MAIB altered small amino acid levels in 
the brain, such as alanine and proline. 
 
Table 5.1.  
NPAA effects on Phe and Tyr in Pah-/- subjects. *mean value in nmol/g 
 
Phenylalanine 
Diet 
(-) 
18% 5% AIB 5% NL 0.5% NB 
(-) 
18%X 3% MAIB 
means* 759 764 333 552 782 671 
p-value 
 
p=0.96 p=0.002 p=0.026 
 
p=0.002 
percent ↓   -1 56 27   14 
       Tyrosine  
Diet 
(-) 
18% 5% AIB 5% NL 0.5% NB 
(-) 
18%X 3% MAIB 
means* 207 144 93 29 28 21 
p-value 
 
p=0.056 p=0.01 p=0.0002 
 
p=0.049 
percent ↓   30 55 86   25 
 
As revealed in these studies, a major challenge will be to minimize LNAA effects 
(other than Phe) with our interventions.  Monoamine and LNAA data indicate that 
5% and 0.5% NL and NB, respectively, are too high and 5% AIB is insufficient for 
optimal intervention. Tyr levels were clearly impacted, and to a lesser extent Met 
and BCAA levels (Fig. 4.1.a).  Moreover, despite an absence of altered Trp 
levels, we observed significant alterations of the serotonin system along with 
dopamine disturbances (Fig. 4.3.a).  Mounting evidence indicates that 
dopaminergic and serotoninergic disruptions in PKU patients contribute 
significantly to long-term pathophysiology (Waisbren et al. 2010; de Groot et al. 
2010; Brumm et al. 2010; Banerjee et al. 2011).  Biosafety information for our 
NPAAs will have utility in terms of preclinical studies.  Anecdotal evidence 
suggests that NL, AIB, NB and MAIB are not extensively metabolized in 
mammals, yet systematic metabolic analyses for any of these compounds is 
lacking, and will also be investigated in further studies.  As well, NPAAs not 
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degraded by mammalian cells may still be metabolized by intestinal bacteria.  For 
example, NL is transaminated in the gut by Candida, and it may be a substrate 
for amino acid oxidase (Der Garabedian and Vermeersch 1987).  Indeed, 
serological data indicates that feeding 5% NL to Pah+/- subjects elevated blood 
urea nitrogen.  AIB (also called 2-methylalanine) is metabolized by at least one 
bacteria (Aaslestad et al. 1964).  No data is available on the metabolism of MAIB 
or NB in mammals.   
 
The approach employing NPAAs should be applicable to another disorder of 
LNAA metabolism, MSUD (maple syrup urine disease), a screenable disorder in 
which the primary amino acids that accumulate to supraphysiological levels are 
leucine, isoleucine and valine.  Knudsen and colleagues (1995) documented 
competition between Phe and Leu for uptake across the BBB in PKU patients, 
and the Km values for Phe (32 + 9 µM) and Leu (87 + 11 µM) uptake into rat brain 
are comparable (Pardridge et al. 1975), all of which leads to the conclusion that 
NPAA intervention should be efficacious in MSUD (Zinnanti et al. 2009).  
Similarities in pathomechanisms do not imply comparable pathophysiology, 
however, and preclinical studies comparable to those outlined above would be 
required in the corresponding MSUD animal model (Skvorak et al 2009a; 2009b; 
Strauss et al. 2010).   
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 6. Future directions 
 
In these studies, the variable of nitrogen load in the control cohort was not fully 
addressed; however, in future studies, casein in control (no NPAA) cohorts will 
be used to attempt to control for nitrogen load with NPAA administration.  Casein, 
a milk protein utilized by Harlan-Teklad in the preparation of their rodent diets 
(www.harlan.com), will be used to attempt to maintain isocaloric and nitrogen-
balanced diets for control cohorts.  Additionally, optimal NPAA interventions will 
be examined in combination with regular (Teklad T.2018M; 18% protein) and low 
protein (Teklad TD.90016; 6% protein) diets that will recapitulate the clinical 
setting of PKU patients.  Similarly, examination of NPAAs in Phe-limited chow 
would most closely mimic the clinical situation for long-term studies. 
 
The long-range goal of these studies is to find a combination of NPAA 
interventions that can selectively block gut absorption and brain transport of Phe 
with minimal impact on other LNAAs.  While optimistic about this goal, an 
additional approach is to consider supplementation of downstream LNAA 
analogues in my studies in the Pahenu2 mouse.  Three compounds, SAMe, 
nitisinone, and 5-HTP (Table 6.1; Fig. 6.1), are proposed to potentially 
circumvent the problems associated with non-Phe inhibition of LAT.  Optimally, 
the intermediates should employ non-LAT systems for brain access, since the 
latter is our therapeutic target.  This is the case for SAMe and nitisinone, but 
remains in question for 5-HTP.  Some evidence suggests that 5-HTP (the 
serotonin precursor) accesses the brain via the serotonin (5-HT) transporter, but 
there is no consensus and it may be partially moved on the LAT (Nakatani et al. 
2008).  The rationale for the application of nitisinone in these studies centers on 
blocking systemic Tyr degradation (the clinical efficacy of this drug applicable to 
tyrosinemia type I) with concomitant elevation of circulating Tyr (McKiernan 
2006).  The latter should lead to increased brain Tyr, but there may be 
competition with the NPAAs.  Nonetheless, additional competition from 5-HTP 
and Tyr (associated with nitisinone administration) with different LATs would be 
desirable and may further curtail brain Phe levels.  Since it utilizes the nucleoside 
transporter, SAMe intervention avoids concerns with LAT competition (Chishty et 
al. 2002), and is rational based upon preliminary findings with NL (Fig. 4.1.a).   
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Table 6.1. 
NPAA interventions proposed to counteract NPAA-related decreases of non-Phe 
LNAAs.  *(NTBC,2 -[2-nitro-4-(trifluoromethyl)benzoyl] cyclohexane-1,3-dione), an 
inhibitor of Tyr degradation. 
Compound Transporter Rationale Citations 
5-HTP 5-HT Bypass LAT, maintain 5-HT 
level 
(Andolina et al. 
2011) 
NTBC* 
Nitisinone 
- Increase systemic Tyr, 
raise DA level 
(McKiernan 2006) 
SAMe Nucleoside Bypass LAT, offset Met 
depletion 
(Chishty et al. 
2002) 
 
 
Figure 6.1. Supplements proposed to bypass LAT.  Chemical structures of 
interventions employed to supplement non-Phe LNAA decreases during NPAA 
intervention. 
 
An additional strategy is supplementation of threonine (Thr).  Segawa and 
colleagues (1999) provided evidence for a Na+-independent intestinal transport 
system for Phe and Thr, and Sanjurjo and coworkers (2003) built upon this 
observation by demonstrating a significant reduction of blood Phe in PKU 
patients receiving Thr supplementation, presumably the result of decreased 
intestinal absorption of Phe due to competition (Sanjurjo et al. 2003). Thr 
supplementation has not been piloted in Pah-/- mice, and its use in combination 
with our NPAAs may provide a more even mix of essential amino acids in the 
murine system, but the risk with Thr feeding is that the patient, or mouse, is 
driven into negative nitrogen balance. Conversely, glycomacropeptide (GMP; 
substantially Phe-free) has been successfully piloted in Pah-/- mice (Ney et al. 
2008; Laclair et al. 2009).  GMP administration significantly increases blood Thr, 
while simultaneously generating an inverse correlation between Thr and Phe in 
brain (decreased Phe with increasing Thr).  Accordingly, GMP may represent 
another mechanism for increasing Thr in Pah-/- mice and further inhibiting Phe 
transport into brain.  In the long run, however, the goal is to utilize only one (or 
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more) of the NPAAs piloted in this thesis work to selectively lower Phe content in 
brain.  The use of additional interventions (SAMe, nitisinone and 5-HTP) would 
be a complicated approach in a patient, might not be significantly more welcome 
by patients than the protein-restricted diet, and actually might have more 
potentially negative downstream metabolic effects than just the NPAAs alone. 
 
Catecholamines in these studies employed ½-brains (sagitally sectioned), which 
may not be optimal.  For example, it is possible that the DA level determined in 
½-brain extract was misleading (Fig. 4.3.a), such that low levels of DA in striatum 
may have been “normalized” via mixing of higher DA levels in cortex or 
cerebellum (or other brain regions) (Bortolozzi et al. 2003).  With this rationale in 
mind, dissected brain regions, including cortex, striatum, cerebellum and 
hippocampi will be monitored during catecholamine measurements in future 
work.  Additionally, neurobehavioral assessments will be made to complement 
terminal catecholamine quantifications once more optimal NPAA interventions 
and combinations are assessed.  The rationale for behavioral assessment 
focuses primarily on the neurocognitive deficits observed in PKU patients 
(Banerjee et al. 2011), as well as the roles of DA and 5-HT in cognition and 
movement (Uddén et al. 2010).  Locomotor, anxiety, and non-spatial memory are 
relevant endpoints for Pah-/- subjects.  For initial motor evaluation, subjects are 
characterized using a quantitative neurological scale (0, normal animal; 10, 
animal displaying near-death recumbency) that examines dystonic movement 
and behavior (Ouary et al. 2000; Zinnanti et al 2009; Zinnanti et al. 2012).  
Visual-cliff avoidance response (CAR) gauges teratological learning impairment 
in mice (Yoshida et al. 2000).  Additionally, open field (OF) activity will be used to 
obtain a broader behavioral coverage of serotoninergic function (Singer et al. 
2009).  The OF test assesses exploratory and anxiety-like behavior, a useful 
measure of behavioral response to novelty (see Fig. 6.2).  The Gibson laboratory 
OF area consists of an enclosed white circular arena, with division markings and 
floor holes.  Animals experiencing higher anxiety will remain in the outermost 
circle of the arena, avoiding the center (thigmotaxis).  In addition, the number of 
head dips and the novel object test evaluates the animal’s exploration of the field.  
Locomotor activity parameters measured include: quadrant transitions and 
velocity, as well as the number of quadrants explored.  These evaluations should 
represent valid surrogates for behavior associated with DA and 5-HT function, 
and can be assessed during intervention without the need to sacrifice the animal.  
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Figure 6.2. Open field testing paradigm for behavioral testing in mice.  Three zone 
groups are established to determine anxiety, non-spatial memory, and locomotor activity. 
 
Finally, since a primary goal of PKU intervention is to examine therapeutic 
strategies that improve cognitive dysfunction, the memory of Pahenu2 mice 
receiving NPAA administration must be explored.  The object recognition (OR) 
test evaluates non-spatial working memory and is based on the premise that 
mice are instinctively curious.  Outputs measures here include the amount of 
time spent in the zone of the familiar versus novel object.  First the activity in the 
arena is recorded in the settings with two familiar objects.  After a rest outside the 
field, the animal is replaced into the same quadrant and left to explore the novel 
object, with the assumption that animals with higher working memory will 
investigate the novel object preferentially (Bevins et al. 2006).  Noldus Ethovision 
software and video recording will be used to track animals in the field, providing 
the outputs described for the OF and novelty testing for the mice.  An example of 
the zoning and quadrature of the field is depicted in Fig. 6.2. Overall, these 
behavioral tests will gauge anxiety, memory, exploratory and locomotor activity 
providing important behavioral readouts for the effectiveness of interventions 
used to treat Pahenu2 mice.  
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7. Conclusion 
 
NL, NB and MAIB have significantly reduced Phe levels in the phenylketonuric 
mouse brain, but with concomitant alterations of important biomolecules for 
serotoninergic and dopaminergic neurotransmission, and other LNAAs.  
Nonetheless, the pilot data shown in this thesis indicates that this novel approach 
is feasible and may be the genesis of a totally new treatment for PKU patients.  
Moreover, for the first time here it is shown that a system A specific inhibitor, 
MAIB, may have important utility as a LAT-1 inhibitor, and this has not been 
reported in the literature.  Utilizing NPAAs to reduce cerebral Phe transport is 
pertinent to the long-term objective of employing oral NPAA intervention(s) in 
patients for whom dietary adherence to low-protein intake is suboptimal, and 
potentially to identify NPAA interventions that would enable normal dietary 
protein intake for patients.  What remains as a barrier is to optimize 
concentration, possibly in combinatorial dosages of NPAA, to produce a cocktail 
with selective Phe-inhibiting capacity.    
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